MedTrace Logo

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

NCT04801095 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-09-16

No results posted yet for this study

Summary

This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

WM-S1-030

WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Wellmarker Bio

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2025-08-08
Completion
2025-08-08

Countries

  • Australia
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04801095 on ClinicalTrials.gov